TGFB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, based on this new mechanistic insight we propose that blockade of TGFβ signalling activity in combination with the Bcr-Abl inhibitor Imatinib could provide a basis for the treatment of drug-resistant CML.